Site icon Nasodren

strong scientific support

Nasodren: strong scientific support

Over the years, many studies to prove the efficacy and safety of Nasodren have been conducted, involving around 2,000 patients. Most of these articles have been published and many of them in journals indexed in PubMed.  
Last April, Rhinology (official Journal of the International Rhinologic Society) published the article “Cyclamen europaeum nasal spray, a novel phytotherapeutic product for the management of acute rhinosinusitis: a randomized double-blind, placebo controlled trial” by Oliver Pfaar et al. From this study we obtain the following key messages:

In March, another unique and impressive study was accepted for publication in The Laryngoscope, (organ of the American Laryngological, Rhinological and Otological Society): “An exploratory Trial of Cyclamen Europaeum Extract for Acute Rhinosinusitis” by J. Ponikau et al.
The key messages learnt from this study are:
In patients with Acute Rhinosinusitis, Cyclamen extract (Nasodren / Sinuforte):

The results of these studies have led, as mentioned above, to the inclusion of Cyclamen europaeum, in the EPOS 2012, the European Guidelines on Rhinosinusitis. Therefore, we can claim to possess a unique product for the treatment of this prevalent condition.

References:
Pfaar O, Mullol J, Anders C, Hormann K, Klimek L. Cyclamen europaeum nasal spray, a novel phytotherapeutic product for the management of acute Rhinosinusitis: a randomized double-blind, placebo-controlled trial. Rhinology. 2012 Mar;50(1):37-44. PMID: 22469604
Ponikau J, Hamilos D, Barreto A, Cecil J, Jones S, Manthei S.  An exploratory trial of Cyclamen europaeum extract for acute Rhinosinusitis. Accepted for publication  Laryngoscope, March, 2012. PMID: 22675486

Exit mobile version